{"id":"https://openalex.org/W2993740971","doi":"https://doi.org/10.1158/1535-7163.targ-19-a118","title":"Abstract A118: Identification of resistance mechanisms to FGFR4 targeted therapy in hepatocellular carcinoma","display_name":"Abstract A118: Identification of resistance mechanisms to FGFR4 targeted therapy in hepatocellular carcinoma","alternate_titles":[],"publication_year":2019,"publication_date":"2019-12-01","ids":{"openalex":"https://openalex.org/W2993740971","doi":"https://doi.org/10.1158/1535-7163.targ-19-a118","mag":"2993740971"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.targ-19-a118","doi":"https://doi.org/10.1158/1535-7163.targ-19-a118","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-19-a118","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2993740971"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5029182005","display_name":"Megan A. Hatlen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Megan A Hatlen","raw_affiliation_strings":["1Blueprint Medicines, Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines, Cambridge, MA;","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065462815","display_name":"Oleg Schmidt\u2010Kittler","orcid":"https://orcid.org/0009-0000-6800-8920","observed_orcids":["https://orcid.org/0009-0000-6800-8920","https://orcid.org/0000-0003-1501-4985"]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Oleg Schmidt-Kittler","raw_affiliation_strings":["1Blueprint Medicines, Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines, Cambridge, MA;","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024845646","display_name":"Cori Ann Sherwin","orcid":"https://orcid.org/0009-0008-8818-4567","observed_orcids":["https://orcid.org/0009-0008-8818-4567"]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Cori-Ann Sherwin","raw_affiliation_strings":["1Blueprint Medicines, Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines, Cambridge, MA;","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076607552","display_name":"Emily Rozsahegyi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Emily Rozsahegyi","raw_affiliation_strings":["1Blueprint Medicines, Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines, Cambridge, MA;","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072574706","display_name":"Nooreen T. Rubin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Nooreen Rubin","raw_affiliation_strings":["1Blueprint Medicines, Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines, Cambridge, MA;","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062122842","display_name":"Michael P. Sheets","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Michael Sheets","raw_affiliation_strings":["1Blueprint Medicines, Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines, Cambridge, MA;","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005920640","display_name":"Joseph L. Kim","orcid":"https://orcid.org/0000-0002-7739-2343","observed_orcids":["https://orcid.org/0000-0002-7739-2343"]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Joseph L Kim","raw_affiliation_strings":["1Blueprint Medicines, Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines, Cambridge, MA;","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046063061","display_name":"Chandra Miduturu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Chandra Miduturu","raw_affiliation_strings":["1Blueprint Medicines, Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines, Cambridge, MA;","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089979299","display_name":"Neil Bifulco","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Neil Bifulco","raw_affiliation_strings":["1Blueprint Medicines, Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines, Cambridge, MA;","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010156999","display_name":"Natasja Brooijmans","orcid":"https://orcid.org/0000-0003-3514-4189","observed_orcids":["https://orcid.org/0000-0003-3514-4189"]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Natasja Brooijmans","raw_affiliation_strings":["1Blueprint Medicines, Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines, Cambridge, MA;","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034389447","display_name":"Hongliang Shi","orcid":"https://orcid.org/0000-0001-9666-1927","observed_orcids":["https://orcid.org/0000-0001-9666-1927"]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Hongliang Shi","raw_affiliation_strings":["1Blueprint Medicines, Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines, Cambridge, MA;","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054293469","display_name":"Timothy J. Guzi","orcid":"https://orcid.org/0000-0002-2620-6897","observed_orcids":["https://orcid.org/0000-0002-2620-6897"]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Timothy Guzi","raw_affiliation_strings":["1Blueprint Medicines, Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines, Cambridge, MA;","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048943840","display_name":"Andy Boral","orcid":"https://orcid.org/0000-0001-6702-630X","observed_orcids":["https://orcid.org/0000-0001-6702-630X"]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Andy Boral","raw_affiliation_strings":["1Blueprint Medicines, Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines, Cambridge, MA;","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020235332","display_name":"Christoph Lengauer","orcid":"https://orcid.org/0000-0002-4498-7228","observed_orcids":["https://orcid.org/0000-0002-4498-7228"]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Christoph Lengauer","raw_affiliation_strings":["1Blueprint Medicines, Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines, Cambridge, MA;","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017360327","display_name":"Marion Dorsch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Marion Dorsch","raw_affiliation_strings":["1Blueprint Medicines, Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines, Cambridge, MA;","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045482037","display_name":"Richard D. Kim","orcid":"https://orcid.org/0000-0002-8448-844X","observed_orcids":["https://orcid.org/0000-0002-8448-844X"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Richard D Kim","raw_affiliation_strings":["2H. Lee Moffitt Cancer Center, Tampa, FL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2H. Lee Moffitt Cancer Center, Tampa, FL;","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005925636","display_name":"Yoon\u2010Koo Kang","orcid":"https://orcid.org/0000-0003-0783-6583","observed_orcids":["https://orcid.org/0000-0003-0783-6583"]},"institutions":[{"id":"https://openalex.org/I2801680663","display_name":"Asan Medical Center","ror":"https://ror.org/03s5q0090","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I2801680663","https://openalex.org/I4210167194"]},{"id":"https://openalex.org/I40542001","display_name":"University of Ulsan","ror":"https://ror.org/02c2f8975","country_code":"KR","type":"education","lineage":["https://openalex.org/I40542001"]}],"countries":["KR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Yoon-Koo Kang","raw_affiliation_strings":["3Asan Medical Center, University of Ulsan College of Medicine, Seoul"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Asan Medical Center, University of Ulsan College of Medicine, Seoul","institution_ids":["https://openalex.org/I2801680663","https://openalex.org/I40542001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061909254","display_name":"Beni B. Wolf","orcid":"https://orcid.org/0009-0008-3809-4280","observed_orcids":["https://orcid.org/0009-0008-3809-4280"]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Beni B Wolf","raw_affiliation_strings":["1Blueprint Medicines, Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines, Cambridge, MA;","institution_ids":["https://openalex.org/I4210100156"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5010844468","display_name":"Klaus P. Hoeflich","orcid":"https://orcid.org/0009-0008-8801-2765","observed_orcids":["https://orcid.org/0009-0008-8801-2765"]},"institutions":[{"id":"https://openalex.org/I4210100156","display_name":"Blueprint Medicines (United States)","ror":"https://ror.org/0142eak56","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100156"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Klaus P Hoeflich","raw_affiliation_strings":["1Blueprint Medicines, Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Blueprint Medicines, Cambridge, MA;","institution_ids":["https://openalex.org/I4210100156"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"reviewed_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"18","issue":"12_Supplement","first_page":"A118","last_page":"A118"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12287","display_name":"Fibroblast Growth Factor Research","score":0.9672999978065491,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12287","display_name":"Fibroblast Growth Factor Research","score":0.9672999978065491,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10073","display_name":"Hepatocellular Carcinoma Treatment and Prognosis","score":0.019999999552965164,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.00860000029206276,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hepatocellular-carcinoma","display_name":"hepatocellular carcinoma","score":0.9660000205039978},{"id":"https://openalex.org/keywords/fgfr4","display_name":"FGFR4","score":0.9440000057220459},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.5199999809265137},{"id":"https://openalex.org/keywords/fgf19","display_name":"FGF19","score":0.9129999876022339},{"id":"https://openalex.org/keywords/gatekeeper-mutations","display_name":"gatekeeper mutation","score":0.7310000061988831},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.7450000047683716},{"id":"https://openalex.org/keywords/oncogenic-drivers","display_name":"oncogenic drivers","score":0.7919999957084656},{"id":"https://openalex.org/keywords/resistance-mutations","display_name":"resistance mutations","score":0.5009999871253967},{"id":"https://openalex.org/keywords/pan-fgfr-inhibitor","display_name":"pan-FGFR inhibitor","score":0.8610000014305115},{"id":"https://openalex.org/keywords/paracrine-signaling","display_name":"paracrine signaling","score":0.6489999890327454},{"id":"https://openalex.org/keywords/structure-based-drug-design","display_name":"structure-based drug design","score":0.5950000286102295},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.5789999961853027},{"id":"https://openalex.org/keywords/liquid-chromatography-tandem-mass-spectrometry","display_name":"liquid chromatography-tandem mass spectrometry","score":0.7149999737739563}],"concepts":[{"id":"https://openalex.org/C2775936931","wikidata":"https://www.wikidata.org/wiki/Q18034920","display_name":"FGF19","level":4,"score":0.7591565251350403},{"id":"https://openalex.org/C66400584","wikidata":"https://www.wikidata.org/wiki/Q5446458","display_name":"Fibroblast growth factor receptor 4","level":5,"score":0.6884630918502808},{"id":"https://openalex.org/C2778019345","wikidata":"https://www.wikidata.org/wiki/Q1148337","display_name":"Hepatocellular carcinoma","level":2,"score":0.65611732006073},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6209206581115723},{"id":"https://openalex.org/C2778695046","wikidata":"https://www.wikidata.org/wiki/Q421136","display_name":"Sorafenib","level":3,"score":0.5598665475845337},{"id":"https://openalex.org/C555283112","wikidata":"https://www.wikidata.org/wiki/Q1637543","display_name":"Carcinogenesis","level":3,"score":0.5207405090332031},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4884142279624939},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4655602276325226},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3800673186779022},{"id":"https://openalex.org/C82867764","wikidata":"https://www.wikidata.org/wiki/Q24780051","display_name":"Fibroblast growth factor receptor","level":4,"score":0.33557236194610596},{"id":"https://openalex.org/C74373430","wikidata":"https://www.wikidata.org/wiki/Q24727126","display_name":"Fibroblast growth factor","level":3,"score":0.31895875930786133},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.31032872200012207},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.13080468773841858}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1535-7163.targ-19-a118","doi":"https://doi.org/10.1158/1535-7163.targ-19-a118","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-19-a118","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9922999739646912,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2978029751","https://openalex.org/W6958993321","https://openalex.org/W2994511758","https://openalex.org/W2977600124","https://openalex.org/W4386757379","https://openalex.org/W2948685669","https://openalex.org/W2739980551","https://openalex.org/W4307906449","https://openalex.org/W2885736997","https://openalex.org/W4200242790"],"abstract_inverted_index":{"When":[0],"on-target":[1],"resistance":[2,71,202,222,257,346],"mutations":[3,72,191,203,254],"occur":[4],"in":[5,59,73,121,129,149,158,195,216,219,270,352],"response":[6,180],"to":[7,85,112,181,234,255,258,294,348],"potent":[8],"and":[9,117,177,188,211,218,248,285,366],"selective":[10],"therapeutics,":[11],"the":[12,52,60,67,88,142,145,240,243,250,287,359],"target":[13],"is":[14,25,138,173,236,246],"often":[15],"considered":[16],"a":[17,26,55,109,130,264],"validated":[18],"driver":[19,56,284],"of":[20,29,57,64,69,92,97,103,126,132,141,144,156,167,179,252,289,345,358],"disease.":[21],"Hepatocellular":[22],"carcinoma":[23,354],"(HCC)":[24],"leading":[27],"cause":[28],"cancer":[30],"mortality":[31],"worldwide":[32],"whose":[33],"drivers":[34],"remain":[35],"unvalidated":[36],"because":[37],"approved":[38],"therapies":[39],"utilize":[40],"multi-kinase":[41],"inhibitors":[42,292],"or":[43,242],"immune":[44],"modulation.":[45],"In":[46],"this":[47],"study,":[48],"we":[49,268],"validate":[50,279],"for":[51,175],"first":[53],"time":[54],"disease":[58,193],"FGF19":[61,127,168],"expressing":[62],"subset":[63,131],"HCC":[65,98,122,133,162],"through":[66,135,215,260],"identification":[68,125],"Fisogatinib":[70,75,157,221,232,259],"FGFR4.":[74,93],"(formerly":[76],"known":[77],"as":[78,169,281],"BLU-554),":[79],"an":[80,282],"investigational":[81],"agent,":[82],"was":[83],"developed":[84],"specifically":[86],"inhibit":[87],"tyrosine":[89],"kinase":[90],"activity":[91],"Approximately":[94],"one":[95],"third":[96],"patients":[99,134,159,197],"harbor":[100],"aberrant":[101],"expression":[102,166],"fibroblast":[104],"growth":[105],"factor":[106],"19":[107],"(FGF19),":[108],"ligand":[110],"hypothesized":[111],"drive":[113],"paracrine":[114],"FGFR4":[115,185,235,349],"activation":[116],"enhance":[118],"mitogenic":[119],"signaling":[120,147],"cells.":[123],"The":[124,151],"amplifications":[128],"genomic":[136],"profiling":[137],"further":[139],"suggestive":[140],"involvement":[143],"FGF19/FGFR4":[146,274,280],"axis":[148],"oncogenesis.":[150],"first-in-human,":[152],"phase":[153],"I":[154],"study":[155],"with":[160,199],"advanced":[161],"(NCT02508467)":[163],"suggests":[164],"that":[165,231],"assessed":[170],"by":[171,207,226],"immunohistochemistry":[172],"responsible":[174],"oncogenesis":[176],"predictive":[178],"treatment.":[182],"We":[183,224],"identified":[184,214],"gatekeeper":[186,241],"(V550)":[187],"hinge-1":[189,244],"(C552)":[190],"upon":[192],"progression":[194],"two":[196],"treated":[198],"Fisogatinib.":[200],"These":[201,277],"had":[204],"been":[205],"predicted":[206],"our":[208],"structure-based":[209],"studies":[210],"were":[212],"also":[213],"vitro":[217],"vivo":[220],"screens.":[223],"confirm":[225],"liquid":[227],"chromatography":[228],"tandem":[229],"mass-spectrometry":[230],"binding":[233],"prevented":[237],"when":[238],"either":[239],"mutation":[245],"present":[247],"demonstrate":[249],"capability":[251],"these":[253],"mediate":[256],"genetic":[261],"engineering.":[262],"Using":[263],"gatekeeper-agnostic":[265],"pan-FGFR":[266],"inhibitor":[267],"show,":[269],"preclinical":[271],"models,":[272],"continued":[273],"pathway":[275],"dependence.":[276],"results":[278],"oncogenic":[283],"inform":[286],"profile":[288],"potential":[290],"next-generation":[291],"designed":[293],"facilitate":[295],"improved":[296],"patient":[297],"outcomes.":[298],"Citation":[299],"Format:":[300],"Megan":[301],"A":[302],"Hatlen,":[303],"Oleg":[304],"Schmidt-Kittler,":[305],"Cori-Ann":[306],"Sherwin,":[307],"Emily":[308],"Rozsahegyi,":[309],"Nooreen":[310],"Rubin,":[311],"Michael":[312],"Sheets,":[313],"Joseph":[314],"L":[315],"Kim,":[316,335],"Chandra":[317],"Miduturu,":[318],"Neil":[319],"Bifulco,":[320],"Natasja":[321],"Brooijmans,":[322],"Hongliang":[323],"Shi,":[324],"Timothy":[325],"Guzi,":[326],"Andy":[327],"Boral,":[328],"Christoph":[329],"Lengauer,":[330],"Marion":[331],"Dorsch,":[332],"Richard":[333],"D":[334],"Yoon-Koo":[336],"Kang,":[337],"Beni":[338],"B":[339],"Wolf,":[340],"Klaus":[341],"P":[342],"Hoeflich.":[343],"Identification":[344],"mechanisms":[347],"targeted":[350],"therapy":[351],"hepatocellular":[353],"[abstract].":[355],"In:":[356],"Proceedings":[357],"AACR-NCI-EORTC":[360],"International":[361],"Conference":[362],"on":[363],"Molecular":[364],"Targets":[365],"Cancer":[367,378],"Therapeutics;":[368],"2019":[369],"Oct":[370],"26-30;":[371],"Boston,":[372],"MA.":[373],"Philadelphia":[374],"(PA):":[375],"AACR;":[376],"Mol":[377],"Ther":[379],"2019;18(12":[380],"Suppl):Abstract":[381],"nr":[382],"A118.":[383],"doi:10.1158/1535-7163.TARG-19-A118":[384]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2993740971","counts_by_year":[],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2019-12-13T00:00:00"}
